Divi's Laboratories Q3 revenue jumped 12.2%; net profit jumped to ₹583 crore

Shares of Divi's Laboratories jumped over 2% on Wednesday after the company announced its quarterly earnings report for the December quarter. The shares later traded ₹6,210 apiece on the NSE at 12:50 pm.

The company’s net profit for the quarter ended December 2025 remained largely unchanged at ₹583 crore as compared to ₹589 crore in the previous year’s same quarter. However, on a sequential basis, the net profit dropped from ₹696 crore in the previous quarter.

The company recorded one-time expenses of ₹74 crore during the quarter as a result of the implementation of new labour codes. Profit before tax (before including the exceptional expense) for the quarter jumped to ₹780 crore as compared to ₹726 crore.

On the topline front, the company’s revenue jumped from ₹2,401 crore to ₹2,692 crore in the Q3FY26. On the operational front, the company’s consolidated EBITDA jumped nearly 20% YoY to ₹898 crore.

The stock was in focus amid the expectations that the company would benefit from entry into obesity and diabetes molecules like Tirezepatide and Orforglipron into the markets.

On a 9MFY26 basis, the company’s revenue jumped 14.8% YoY and net profit surged by 18.5% YoY.

Divi’s Laboratories is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generics, the Company, through its custom synthesis, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late-life cycle management

The Company has two wholly owned subsidiaries which are Divis Laboratories (USA) Inc in USA and Divi’s Laboratories Europe AG in Switzerland; engaged in marketing/distribution of nutraceutical ingredients used in the food, beverage, dietary supplement, feed and pet food industries providing a greater reach to customers within these regions.